Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy

Xu,Da; Liu,Xiao‑Feng; Yan,Xiao‑Luan; Wang,Kun; Xing,Bao‑Cai

doi:10.3892/ol.2017.7191

Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy

Authors:
- Da Xu
- Xiao‑Feng Liu
- Xiao‑Luan Yan
- Kun Wang
- Bao‑Cai Xing
View Affiliations

Affiliations: Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, P.R. China, Department of Cell Biology, School of Basic Medical Research, Peking University Health Science Center, Beijing 100191, P.R. China
Published online on: October 16, 2017 https://doi.org/10.3892/ol.2017.7191
Pages: 8051-8059
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical risk scores and response to pre‑operative chemotherapy are prognostic factors of colorectal liver metastases. The aim of the present study was to evaluate the effectiveness of combining these factors to predict patient survival and to select patients for curative therapy. The study included 189 patients who underwent hepatectomy following neo‑adjuvant chemotherapy, for initially resectable colorectal liver metastases, between January 2005 and December 2015. Patients were stratified into four sub‑groups: A1‑2, low clinical risk scores with/without a response to pre‑operative chemotherapy; and B1‑2, high clinical risk scores with or without a response to pre‑operative chemotherapy. Treatment and survival data were analysed. Survival was significantly longer in patients with low clinical risk scores and a response to pre‑operative chemotherapy; these factors were confirmed as independent prognostic factors by multivariate analysis. Combining clinical risk score and chemotherapy response classification, patient survival was significantly longer for groups A1‑2/B1 compared with for group B2, in which only 10.2% of patients were alive after 5 years. Of those with no response to first‑line chemotherapy, survival was significantly longer in patients who responded to second‑line chemotherapy. A combined clinical risk score and chemotherapy response classification may aid in identifying suitable candidates for potentially curative therapy.

View Figures

View References

1	Smith JJ and D'Angelica MI: Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin North Am. 29:61–84. 2015. View Article : Google Scholar : PubMed/NCBI
2	Leporrier J, Maurel J, Chiche L, Bara S, Segol P and Launoy G: A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 93:465–474. 2006. View Article : Google Scholar : PubMed/NCBI
3	Rees M, Tekkis PP, Welsh FK, O'Rourke T and John TG: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg. 247:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
4	Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D and Abdalla EK: Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg. 141:460–467. 2006. View Article : Google Scholar : PubMed/NCBI
5	Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ and Rees M: Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer. 94:982–999. 2006. View Article : Google Scholar : PubMed/NCBI
6	Nakai T, Ishikawa H, Tokoro T and Okuno K: The clinical risk score predicts the effectiveness of adjuvant chemotherapy for colorectal liver metastasis. World J Surg. 39:1527–1536. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA and Poston G: Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin Epidemiol. 4:283–301. 2012.PubMed/NCBI
8	Petrelli NJ: Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol. 26:4862–4863. 2008. View Article : Google Scholar : PubMed/NCBI
9	Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
10	Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J and Koch M: Adjuvant therapy after resection of colorectal liver metastases: The predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 14:1742014. View Article : Google Scholar : PubMed/NCBI
11	Mann CD, Metcalfe MS, Leopardi LN and Maddern GJ: The clinical risk score: Emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 139:1168–1172. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ayez N, van der Stok EP, Grunhagen DJ, Rothbarth J, van Meerten E, Eggermont AM and Verhoef C: The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Eur J Surg Oncol. 41:859–867. 2015. View Article : Google Scholar : PubMed/NCBI
13	Reddy SK, Kattan MW, Yu C, Ceppa EP, de la Fuente SG, Fong Y, Clary BM and White RR: Evaluation of peri-operative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases. HPB (Oxford). 11:592–599. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kumar R, Dennison AR, Robertson V, Jones MJ, Neal CP and Garcea G: Clinical risk scores in the current era of neoadjuvant chemotherapy for colorectal liver metastases. ANZ J Surg. Sep 12–2016.(Epub ahead of print). View Article : Google Scholar
15	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013. View Article : Google Scholar : PubMed/NCBI
16	Baize N, Gerard B, Bleiberg H, Caroli-Bosc F, Berthier F, Legendre H, Pector JC and Hendlisz A: Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol Clin Biol. 30:1349–1353. 2006. View Article : Google Scholar : PubMed/NCBI
17	Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg. 240:644–658. 2004.PubMed/NCBI
18	Vessie EL, Liu DM, Forster B, Kos S, Baxter K, Gagnon J and Klass D: A practical guide to magnetic resonance vascular imaging: Techniques and applications. Ann Vasc Surg. 28:1052–1061. 2014. View Article : Google Scholar : PubMed/NCBI
19	Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L and Fong Y: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 7:109–117. 2003. View Article : Google Scholar : PubMed/NCBI
20	Vigano L, Capussotti L, Barroso E, Nuzzo G, Laurent C, Ijzermans JN, Gigot JF, Figueras J, Gruenberger T, Mirza DF, et al: Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol. 19:2786–2796. 2012. View Article : Google Scholar : PubMed/NCBI
21	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zendel A, Lahat E, Dreznik Y, Zakai BB, Eshkenazy R and Ariche A: ‘Vanishing liver metastases’-A real challenge for liver surgeons. Hepatobiliary Surg Nutr. 3:295–302. 2014.PubMed/NCBI
23	Jones RP, Stattner S, Sutton P, Dunne DF, McWhirter D, Fenwick SW, Malik HZ and Poston GJ: Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg Oncol. 23:53–60. 2014. View Article : Google Scholar : PubMed/NCBI
24	Clavien PA, Petrowsky H, DeOliveira ML and Graf R: Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 356:1545–1559. 2007. View Article : Google Scholar : PubMed/NCBI
25	Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, et al: Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 23:2619–2626. 2012. View Article : Google Scholar : PubMed/NCBI
26	Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J and Ruers TJ: Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 50:912–919. 2014. View Article : Google Scholar : PubMed/NCBI
27	Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F and Bismuth H: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg. 240:1052–1064. 2004. View Article : Google Scholar : PubMed/NCBI
28	Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R and Neuhaus P: Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery. 146:52–59. 2009. View Article : Google Scholar : PubMed/NCBI
29	Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ and Kemeny N: Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol. 16:1844–1851. 2009. View Article : Google Scholar : PubMed/NCBI
30	Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, et al: The oncosurgery approach to managing liver metastases from colorectal cancer: A multidisciplinary international consensus. Oncologist. 17:1225–1239. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI
32	Levi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, et al: Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 27:267–274. 2016. View Article : Google Scholar : PubMed/NCBI
33	De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 19:508–515. 2008. View Article : Google Scholar : PubMed/NCBI
34	Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 28:466–474. 2010. View Article : Google Scholar : PubMed/NCBI
35	Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI